Jiao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiao Zhang has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Taylor
Texas Children’s Hospital, Baylor College of Medicine , Houston, Texas
15 shared publications - Hiromichi Suzuki
Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
13 shared publications - Jüri Reimand
Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Canada
12 shared publications - Maria Vladoiu
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
12 shared publications - Pasqualino De Antonellis
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
12 shared publications - Alexandra Rasnitsyn
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
11 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (10)
Regulatory-prior-guided attention preserves biological structure during unpaired single-cell RNA–ATAC integration
Motivation: Single-cell RNA sequencing and single-cell ATAC sequencing provide complementary views of transcriptional output and chromatin regulatory potential, but integrating unpaired profiles remains challenging because the modalities differ in feature space, sparsity and noise. Existing approaches often frame integration as distribution matching, which can over-align biologically distinct, condition-specific or modality-specific cell states. We present scHPGT, a single-cell Heterogeneous Prior-Guided Transformer for regulatory-prior-guided integration of unpaired RNA and chromatin accessibility profiles. scHPGT uses modality-specific encoders to model RNA and ATAC signals, a prior-guided cross-modal Transformer to constrain gene–peak attention using regulatory links, and a domain-adversarial objective to reduce modality-specific discrepancies in a shared latent space. Results: Across PBMC3k, mouse spleen, CITE-seq/ASAP-seq PBMC and PBMC10k benchmarks, scHPGT improves clustering agreement, label transfer and biological structure preservation while maintaining effective modality alignment. In partial-overlap and condition-shift settings, scHPGT aligns shared populations without forcing unmatched or condition-specific states into inappropriate correspondence. Attention-derived links recover regulatory relationships, highlight marker-gene regulatory regions, recover transcription factor programs and produce regulatory activity profiles consistent with cell-type-specific transcriptional programs. Availability and Implementation: Code and datasets are released at https://github.com/zlCreator/scHPGT.
- 18 September 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (10)
Open AccessRegulatory-prior-guided attention preserves biological structure during unpaired single-cell RNA–ATAC integration
Motivation: Single-cell RNA sequencing and single-cell ATAC sequencing provide complementary views of transcriptional output and chromatin regulatory potential, but integrating unpaired profiles remains challenging because the modalities differ in feature space, sparsity and noise. Existing approaches often frame integration as distribution matching, which can over-align biologically distinct, condition-specific or modality-specific cell states. We present scHPGT, a single-cell Heterogeneous Prior-Guided Transformer for regulatory-prior-guided integration of unpaired RNA and chromatin accessibility profiles. scHPGT uses modality-specific encoders to model RNA and ATAC signals, a prior-guided cross-modal Transformer to constrain gene–peak attention using regulatory links, and a domain-adversarial objective to reduce modality-specific discrepancies in a shared latent space. Results: Across PBMC3k, mouse spleen, CITE-seq/ASAP-seq PBMC and PBMC10k benchmarks, scHPGT improves clustering agreement, label transfer and biological structure preservation while maintaining effective modality alignment. In partial-overlap and condition-shift settings, scHPGT aligns shared populations without forcing unmatched or condition-specific states into inappropriate correspondence. Attention-derived links recover regulatory relationships, highlight marker-gene regulatory regions, recover transcription factor programs and produce regulatory activity profiles consistent with cell-type-specific transcriptional programs. Availability and Implementation: Code and datasets are released at https://github.com/zlCreator/scHPGT.
- Open Access
- 25 March 2026
- Published by Springer Nature in Nature
- Vol. 652 (8110) , 763-773
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma
Posterior fossa type A (PFA) ependymoma is an unusual infantile brain tumour with few known somatic mutations, thought to be driven by epigenetic mechanisms1. PFA ependymoma has a markedly higher incidence and worse prognosis in male children than in female children2. The mechanisms that underlie these sex differences are at present unknown. Here we show that the cellular hierarchy of PFA ependymoma is less differentiated in male individuals than it is in female individuals. In the normal developing mouse hindbrain, male gliogenic progenitors are less differentiated than matched female sibling controls. To further parse the effects of chromosomal versus gonadal contributions in the male hindbrain, we used the four-core genotype mouse model3, which showed that androgen signalling, rather than sex chromosomes, prolongs hindbrain differentiation in male mice. Androgen supplementation promotes the growth of PFA ependymoma, but not that of other brain tumours. Conversely, androgen blockade diminishes both the stem-like potential and the proliferation of PFA ependymoma. We conclude that androgen signalling in both the normal developing hindbrain and PFA ependymoma is sufficient to promote growth and delay differentiation. Anti-androgen therapies represent a potential clinical avenue to target this currently untreatable childhood cancer.
- 25 March 2026
- Published by Springer Nature in Nature
- Vol. 652 (8110) , 763-773
Open AccessAndrogen activity in the male embryonic hindbrain drives lethal PFA ependymoma
Posterior fossa type A (PFA) ependymoma is an unusual infantile brain tumour with few known somatic mutations, thought to be driven by epigenetic mechanisms1. PFA ependymoma has a markedly higher incidence and worse prognosis in male children than in female children2. The mechanisms that underlie these sex differences are at present unknown. Here we show that the cellular hierarchy of PFA ependymoma is less differentiated in male individuals than it is in female individuals. In the normal developing mouse hindbrain, male gliogenic progenitors are less differentiated than matched female sibling controls. To further parse the effects of chromosomal versus gonadal contributions in the male hindbrain, we used the four-core genotype mouse model3, which showed that androgen signalling, rather than sex chromosomes, prolongs hindbrain differentiation in male mice. Androgen supplementation promotes the growth of PFA ependymoma, but not that of other brain tumours. Conversely, androgen blockade diminishes both the stem-like potential and the proliferation of PFA ependymoma. We conclude that androgen signalling in both the normal developing hindbrain and PFA ependymoma is sufficient to promote growth and delay differentiation. Anti-androgen therapies represent a potential clinical avenue to target this currently untreatable childhood cancer.
- 19 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (6) , 1556-1570
Targeting tumor-associated macrophage-induced IGF1/PI3K/Zic1 axis triggers SHH medulloblastoma regression and chemosensitization
Tumor-associated macrophages (TAMs) are key contributors to the brain tumor microenvironment. However, their role in medulloblastoma (MB) progression and chemoresistance remains elusive. We utilized CD11b-diphtheria toxin receptor (DTR)/Ptch1-deficient MB model to genetically delete TAMs. NeuroD2-SmoA1 MB mice were treated with CSF1R inhibitor PLX3397, PI3K inhibitor buparlisib, and a combination of PLX3397 with chemotherapy to examine the functional significance of TAMs in MB. Tumor tissues and cell co-culture system were analyzed using RNA sequencing (RNA-seq), Western blotting, flow cytometry, immunohistochemistry, quantitative PCR and 3D bioprinted MB mono-culture to delineate mechanistic interactions. Myeloid-derived TAMs are abundant in MB tissues and primarily exhibit M2-like polarization. We demonstrate that TAMs depletion, achieved either genetically via diphtheria toxin (DT) or pharmacologically via PLX3397-mediated preferential targeting of M2-like TAMs, markedly downregulates Zic1 expression and impedes MB growth. Mechanistically, M2-like TAMs secreted high levels of IGF1 to activate the PI3K/mTOR/Zic1 axis in MB cells; whereas the PI3K inhibitor buparlisib effectively reduced the population of Zic1-expresssing cells and restricted MB growth. Notably, the PI3K/mTOR/Zic1 axis was demonstrated to confer chemoresistance. While chemotherapy exacerbates M2-like TAMs accumulation within MB, combining PLX3397 with chemotherapy abrogates this infiltration and attenuates IGF1/PI3K/Zic1 signaling axis. This combination strategy synergistically inhibits tumor growth and extends survival in mice. Our findings demonstrate that inhibiting the TAMs-induced IGF1/PI3K/Zic1 signaling axis results in MB regression and chemosensitization. These results underscore the therapeutic potential of combining clinical CSF1R inhibitor with standard chemotherapy as an effective treatment strategy for SHH MB.
- 19 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (6) , 1556-1570
Targeting tumor-associated macrophage-induced IGF1/PI3K/Zic1 axis triggers SHH medulloblastoma regression and chemosensitization
Tumor-associated macrophages (TAMs) are key contributors to the brain tumor microenvironment. However, their role in medulloblastoma (MB) progression and chemoresistance remains elusive. We utilized CD11b-diphtheria toxin receptor (DTR)/Ptch1-deficient MB model to genetically delete TAMs. NeuroD2-SmoA1 MB mice were treated with CSF1R inhibitor PLX3397, PI3K inhibitor buparlisib, and a combination of PLX3397 with chemotherapy to examine the functional significance of TAMs in MB. Tumor tissues and cell co-culture system were analyzed using RNA sequencing (RNA-seq), Western blotting, flow cytometry, immunohistochemistry, quantitative PCR and 3D bioprinted MB mono-culture to delineate mechanistic interactions. Myeloid-derived TAMs are abundant in MB tissues and primarily exhibit M2-like polarization. We demonstrate that TAMs depletion, achieved either genetically via diphtheria toxin (DT) or pharmacologically via PLX3397-mediated preferential targeting of M2-like TAMs, markedly downregulates Zic1 expression and impedes MB growth. Mechanistically, M2-like TAMs secreted high levels of IGF1 to activate the PI3K/mTOR/Zic1 axis in MB cells; whereas the PI3K inhibitor buparlisib effectively reduced the population of Zic1-expresssing cells and restricted MB growth. Notably, the PI3K/mTOR/Zic1 axis was demonstrated to confer chemoresistance. While chemotherapy exacerbates M2-like TAMs accumulation within MB, combining PLX3397 with chemotherapy abrogates this infiltration and attenuates IGF1/PI3K/Zic1 signaling axis. This combination strategy synergistically inhibits tumor growth and extends survival in mice. Our findings demonstrate that inhibiting the TAMs-induced IGF1/PI3K/Zic1 signaling axis results in MB regression and chemosensitization. These results underscore the therapeutic potential of combining clinical CSF1R inhibitor with standard chemotherapy as an effective treatment strategy for SHH MB.
- Open Access
- 10 March 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 134
An interpretable machine learning model for predicting prognosis of medulloblastoma integrating genetic and clinical features
Background Medulloblastoma (MB), the most common malignant pediatric brain tumor, lacks prognostic tools integrating clinical, molecular, and treatment-related characteristics for individualized management. Methods We developed machine learning models using multicenter data from 729 Chinese patients (2001-2023), of whom 509 were assigned to the training set and 220 to the testing set, and further validated the models on 201 patients from international MB consortia. To accommodate patients and researchers with varying datatypes, four application scenarios were established, including clinical-molecular-radiotherapy (CMR), clinical-molecular (CM), clinical-radiotherapy (CR), and clinical-only (CO). Results We construct four model scenarios and assess their predictive performance in the testing set: an XGBoost-based CMR model (incorporating 11 features, including molecular subgroup, radiotherapy dose, and key gene expression) with a C-index of 0.612; an XGBoost-based CM (C-index = 0.609); a GBM-based CR (C-index = 0.637); and a GBM-based CO (C-index = 0.635). External validation demonstrates robust performance, with radiotherapy and molecular data contributing significantly to enhanced efficacy. In addition, interactive web-based Shiny applications have been launched to facilitate dynamic risk assessment and treatment optimization. Conclusions By integrating multidimensional data, our framework enables the tailored prognostication and clinical decision to meet the multidimensional requirements of research and medicine.
- 10 March 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 134
Open AccessAn interpretable machine learning model for predicting prognosis of medulloblastoma integrating genetic and clinical features
Background Medulloblastoma (MB), the most common malignant pediatric brain tumor, lacks prognostic tools integrating clinical, molecular, and treatment-related characteristics for individualized management. Methods We developed machine learning models using multicenter data from 729 Chinese patients (2001-2023), of whom 509 were assigned to the training set and 220 to the testing set, and further validated the models on 201 patients from international MB consortia. To accommodate patients and researchers with varying datatypes, four application scenarios were established, including clinical-molecular-radiotherapy (CMR), clinical-molecular (CM), clinical-radiotherapy (CR), and clinical-only (CO). Results We construct four model scenarios and assess their predictive performance in the testing set: an XGBoost-based CMR model (incorporating 11 features, including molecular subgroup, radiotherapy dose, and key gene expression) with a C-index of 0.612; an XGBoost-based CM (C-index = 0.609); a GBM-based CR (C-index = 0.637); and a GBM-based CO (C-index = 0.635). External validation demonstrates robust performance, with radiotherapy and molecular data contributing significantly to enhanced efficacy. In addition, interactive web-based Shiny applications have been launched to facilitate dynamic risk assessment and treatment optimization. Conclusions By integrating multidimensional data, our framework enables the tailored prognostication and clinical decision to meet the multidimensional requirements of research and medicine.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy